Key regions: United Kingdom, Brazil, Europe, France, Canada
The demand for Anti-Fibrinolytic Drugs in Jordan has been growing steadily in recent years.
Customer preferences: One of the primary reasons for this growth is the increasing prevalence of bleeding disorders in Jordan. Patients suffering from conditions such as hemophilia, liver disease, and trauma-related injuries require Anti-Fibrinolytic Drugs to control excessive bleeding. Additionally, the aging population in Jordan has led to an increase in the number of patients suffering from cardiovascular diseases, which also require the use of these drugs.
Trends in the market: The market for Anti-Fibrinolytic Drugs in Jordan is expected to continue growing in the coming years. This growth is driven by the increasing awareness of bleeding disorders and the availability of advanced treatment options. Additionally, the government of Jordan has been investing in the healthcare sector, which is expected to further boost the demand for these drugs.
Local special circumstances: One of the unique aspects of the Anti-Fibrinolytic Drugs market in Jordan is the role of traditional medicine. Many patients in Jordan still rely on traditional remedies for the treatment of bleeding disorders, which can limit the growth of the market for modern drugs. However, the increasing availability of modern drugs and the efforts of healthcare providers to educate patients on the benefits of these drugs are expected to overcome this challenge.
Underlying macroeconomic factors: The overall economic growth in Jordan is also expected to contribute to the growth of the Anti-Fibrinolytic Drugs market. The country has been implementing economic reforms to attract foreign investment and promote economic growth. This is expected to lead to an increase in the availability of healthcare services, including the availability of Anti-Fibrinolytic Drugs. Additionally, the government has been investing in the healthcare sector, which is expected to further boost the demand for these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
